BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 21136030)

  • 1. Investigations on parotid gland recovery after IMRT in head and neck tumor patients.
    Stock M; Dörr W; Stromberger C; Mock U; Koizar S; Pötter R; Georg D
    Strahlenther Onkol; 2010 Dec; 186(12):665-71. PubMed ID: 21136030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of salivary gland function after treatment of head-and-neck tumors with intensity-modulated radiotherapy by quantitative pertechnetate scintigraphy.
    Münter MW; Karger CP; Hoffner SG; Hof H; Thilmann C; Rudat V; Nill S; Wannenmacher M; Debus J
    Int J Radiat Oncol Biol Phys; 2004 Jan; 58(1):175-84. PubMed ID: 14697436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can dose reduction to one parotid gland prevent xerostomia?--A feasibility study for locally advanced head and neck cancer patients treated with intensity-modulated radiotherapy.
    Anand AK; Jain J; Negi PS; Chaudhoory AR; Sinha SN; Choudhury PS; Kumar R; Munjal RK
    Clin Oncol (R Coll Radiol); 2006 Aug; 18(6):497-504. PubMed ID: 16909975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longitudinal assessment of parotid function in patients receiving tomotherapy for head-and-neck cancer.
    Voordeckers M; Everaert H; Tournel K; Verellen D; Baron I; Van Esch G; Vanhove C; Storme G
    Strahlenther Onkol; 2008 Aug; 184(8):400-5. PubMed ID: 18956516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in salivary gland function after radiotherapy of head and neck tumors measured by quantitative pertechnetate scintigraphy: comparison of intensity-modulated radiotherapy and conventional radiation therapy with and without Amifostine.
    Münter MW; Hoffner S; Hof H; Herfarth KK; Haberkorn U; Rudat V; Huber P; Debus J; Karger CP
    Int J Radiat Oncol Biol Phys; 2007 Mar; 67(3):651-9. PubMed ID: 17175118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Scintigraphic assessment of salivary function after intensity-modulated radiotherapy for head and neck cancer: correlations with parotid dose and quality of life.
    Chen WC; Lai CH; Lee TF; Hung CH; Liu KC; Tsai MF; Wang WH; Chen H; Fang FM; Chen MF
    Oral Oncol; 2013 Jan; 49(1):42-8. PubMed ID: 22854066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: initial results.
    Chao KS; Deasy JO; Markman J; Haynie J; Perez CA; Purdy JA; Low DA
    Int J Radiat Oncol Biol Phys; 2001 Mar; 49(4):907-16. PubMed ID: 11240231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recovery of Salivary Function: Contralateral Parotid-sparing Intensity-modulated Radiotherapy versus Bilateral Superficial Lobe Parotid-sparing Intensity-modulated Radiotherapy.
    Miah AB; Gulliford SL; Morden J; Newbold KL; Bhide SA; Zaidi SH; Hall E; Harrington KJ; Nutting CM
    Clin Oncol (R Coll Radiol); 2016 Sep; 28(9):e69-e76. PubMed ID: 26994893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of salivary gland dosimetry on post-IMRT recovery of saliva output and xerostomia grade for head-and-neck cancer patients treated with or without contralateral submandibular gland sparing: a longitudinal study.
    Wang ZH; Yan C; Zhang ZY; Zhang CP; Hu HS; Tu WY; Kirwan J; Mendenhall WM
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1479-87. PubMed ID: 20934262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parotid glands dose-effect relationships based on their actually delivered doses: implications for adaptive replanning in radiation therapy of head-and-neck cancer.
    Hunter KU; Fernandes LL; Vineberg KA; McShan D; Antonuk AE; Cornwall C; Feng M; Schipper MJ; Balter JM; Eisbruch A
    Int J Radiat Oncol Biol Phys; 2013 Nov; 87(4):676-82. PubMed ID: 24035328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parotid gland sparing with helical tomotherapy in head-and-neck cancer.
    Voordeckers M; Farrag A; Everaert H; Tournel K; Storme G; Verellen D; De Ridder M
    Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):443-8. PubMed ID: 22836056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensity modulated radiation therapy for oropharyngeal and oral cavity tumors: clinical use and experience.
    Claus F; Duthoy W; Boterberg T; De Gersem W; Huys J; Vermeersch H; De Neve W
    Oral Oncol; 2002 Sep; 38(6):597-604. PubMed ID: 12167438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preservation of oral health-related quality of life and salivary flow rates after inverse-planned intensity- modulated radiotherapy (IMRT) for head-and-neck cancer.
    Parliament MB; Scrimger RA; Anderson SG; Kurien EC; Thompson HK; Field GC; Hanson J
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):663-73. PubMed ID: 14967418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dosimetric predictors of xerostomia for head-and-neck cancer patients treated with the smart (simultaneous modulated accelerated radiation therapy) boost technique.
    Amosson CM; Teh BS; Van TJ; Uy N; Huang E; Mai WY; Frolov A; Woo SY; Chiu JK; Carpenter LS; Lu HH; Grant WH; Butler EB
    Int J Radiat Oncol Biol Phys; 2003 May; 56(1):136-44. PubMed ID: 12694832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring dosimetric impact of weight loss with kilovoltage (kV) cone beam CT (CBCT) during parotid-sparing IMRT and concurrent chemotherapy.
    Ho KF; Marchant T; Moore C; Webster G; Rowbottom C; Penington H; Lee L; Yap B; Sykes A; Slevin N
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):e375-82. PubMed ID: 22197229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose, volume, and function relationships in parotid salivary glands following conformal and intensity-modulated irradiation of head and neck cancer.
    Eisbruch A; Ten Haken RK; Kim HM; Marsh LH; Ship JA
    Int J Radiat Oncol Biol Phys; 1999 Oct; 45(3):577-87. PubMed ID: 10524409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of xerostomia incidence after three-dimensional conformal radiation therapy and contralateral superficial lobe parotid-sparing intensity-modulated radiotherapy for oropharyngeal and hypopharyngeal cancer.
    Kawamoto T; Nihei K; Nakajima Y; Kito S; Sasai K; Karasawa K
    Auris Nasus Larynx; 2018 Oct; 45(5):1073-1079. PubMed ID: 29397249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diffusion-weighted magnetic resonance imaging to evaluate major salivary gland function before and after radiotherapy.
    Dirix P; De Keyzer F; Vandecaveye V; Stroobants S; Hermans R; Nuyts S
    Int J Radiat Oncol Biol Phys; 2008 Aug; 71(5):1365-71. PubMed ID: 18355977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of amifostine or IMRT to preserve the parotid function after radiotherapy of the head and neck region measured by quantitative salivary gland scintigraphy.
    Rudat V; Münter M; Rades D; Grötz KA; Bajrovic A; Haberkorn U; Brenner W; Debus J
    Radiother Oncol; 2008 Oct; 89(1):71-80. PubMed ID: 18707782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective longitudinal assessment of parotid gland function using dynamic quantitative pertechnate scintigraphy and estimation of dose-response relationship of parotid-sparing radiotherapy in head-neck cancers.
    Gupta T; Hotwani C; Kannan S; Master Z; Rangarajan V; Murthy V; Budrukkar A; Ghosh-Laskar S; Agarwal JP
    Radiat Oncol; 2015 Mar; 10():67. PubMed ID: 25889705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.